Gastroesophageal reflux disease (GERD) is a common gastrointestinal disease, and proton pump inhibitors (PPIs) have been recommended as the first-line treatment for GERD. In recent years, studies on vonoprazan fumarate in the treatment of GERD have attracted widespread attention. In this paper, we review the research progress of vonoprazan fumarate and proton pump inhibitors in the treatment of GERD in recent years, and compare and analyze the efficacy, safety, tolerability, and advantages and disadvantages of long-term application of both. By reviewing the relevant literature, we found that vonoprazan fumarate has similar performance with proton pump inhibitors in terms of efficacy and safety, but has potential advantages in terms of tolerability and long-term application. Therefore, we believe that vonoprazan fumarate may become a new option for GERD treatment, helping clinicians to develop more appropriate treatment plans for patients and providing new ideas and directions for research in related fields.
References
[1]
Eusebi, L.H., Ratnakumaran, R., Yuan, Y., et al. (2018) Global Prevalence Of, and Risk Factors For, Gastro-Oesophageal Reflux Symptoms: A Meta-Analysis. Gut, 67, 430-440. https://doi.org/10.1136/gutjnl-2016-313589
[2]
Lagergren, J., Smyth, E., Cunningham, D. and Lagergren, P. (2017) Oesophageal Cancer. Lancet, 390, 2383-2396. https://doi.org/10.1016/S0140-6736(17)31462-9
[3]
El-Serag, H.B., Sweet, S., Winchester, C.C. and Dent, J. (2014) Update on the Epidemiology of Gastro-Oesophageal Reflux Disease: A Systematic Review. Gut, 63, 871-880. https://doi.org/10.1136/gutjnl-2012-304269
[4]
Katz, P.O., Gerson, L.B. and Vela, M.F. (2013) Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology, 108, 308-328. https://doi.org/10.1038/ajg.2012.444
[5]
Fass, R. (2009) Proton Pump Inhibitor Failure—What Are the Therapeutic Options? American Journal of Gastroenterology, 104, S33-S38.
[6]
Ito, T. and Jensen, R.T. (2010) Association of Long-Term Proton Pump Inhibitor Therapy with Bone Fractures and Effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium. Current Gastroenterology Reports, 12, 448-457. https://doi.org/10.1007/s11894-010-0141-0
[7]
Sakurai, Y., Mori, Y., Okamoto, H., et al. (2015) Acid-Inhibitory Effects of Vonoprazan 20 mg Compared with Esomeprazole 20 mg or Rabeprazole 10 mg in Healthy Adult Male Subjects—A Randomised Open-Label Cross-Over Study. Alimentary Pharmacology & Therapeutics, 42, 719-730. https://doi.org/10.1111/apt.13325
[8]
Jenkins, H., Sakurai, Y., Nishimura, A., et al. (2015) Randomised Clinical Trial: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeated Doses of TAK-438 (Vonoprazan), a Novel Potassium-Competitive Acid Blocker, in Healthy Male Subjects. Alimentary Pharmacology & Therapeutics, 41, 636-648. https://doi.org/10.1111/apt.13121
[9]
Miwa, H., Uedo, N., Watari, J., et al. (2017) Randomised Clinical Trial: Efficacy and Safety of Vonoprazan vs. Lansoprazole in Patients with Gastric or Duodenal Ulcers—Results from Two Phase 3, Non-Inferiority Randomised Controlled Trials. Alimentary Pharmacology & Therapeutics, 45, 240-252. https://doi.org/10.1111/apt.13876
[10]
Iwakiri, K., Sakurai, Y., Shiino, M., et al. (2017) A Randomized, Double-Blind Study to Evaluate the Acid-Inhibitory Effect of Vonoprazan (20 mg and 40 mg) in Patients with Proton-Pump Inhibitor-Resistant Erosive Esophagitis. Therapeutic Advances in Gastroenterology, 10, 439-451. https://doi.org/10.1177/1756283X17705329
[11]
Shin, J.M. and Sachs, G.(2004) Differences in Binding Properties of Two Proton Pump Inhibitors on the Gastric H+,K+-ATPase in Vivo. Biochemical Pharmacology, 68, 2117-2127. https://doi.org/10.1016/j.bcp.2004.07.035
[12]
Yuan, Y., Ford, A.C., Khan, K.J., et al. (2013) Optimum Duration of Regimens for Helicobacter pylori Eradication. Cochrane Database of Systematic Reviews, No. 12, Article No. CD008337. https://doi.org/10.1002/14651858.CD008337.pub2
[13]
Freedberg, D.E., Kim, L.S. and Yang, Y.-X. (2017) The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology, 152, 706-715. https://doi.org/10.1053/j.gastro.2017.01.031
[14]
Vakil, N., Van Zanten, S. V., Kahrilas, P., et al. (2006) The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. American Journal of Gastroenterology, 101, 1900-1920.
[15]
Shaw, M.J., Talley, N.J., Beebe, T.J., et al. (2001) Initial Validation of a Diagnostic Questionnaire for Gastroesophageal Reflux Disease. American Journal of Gastroenterology, 96, 52-57. https://doi.org/10.1111/j.1572-0241.2001.03451.x
[16]
Lundell, L.R., Dent, J., Bennett, J.R., et al. (1999) Endoscopic Assessment of Oesophagitis: Clinical and Functional Correlates and Further Validation of the Los Angeles Classification. Gut, 45, 172-180. https://doi.org/10.1136/gut.45.2.172
[17]
Kahrilas, P.J., Shaheen, N.J. and Vaezi, M.F. (2008) American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease. Gastroenterology, 135, 1383-1391. https://doi.org/10.1053/j.gastro.2008.08.045
[18]
Ashida, K., Sakurai, Y., Hori, T., et al. (2016) Randomised Clinical Trial: Vonoprazan, a Novel Potassium-Competitive Acid Blocker, vs. Lansoprazole for the Healing of Erosive Oesophagitis. Alimentary Pharmacology & Therapeutics, 43, 240-251. https://doi.org/10.1111/apt.13461
[19]
Miyazaki, H., Igarashi, A., Takeuchi, T., et al. (2019) Vonoprazan versus Proton-Pump Inhibitors for Healing Gastroesophageal Reflux Disease: A Systematic Review. Journal of Gastroenterology and Hepatology, 34, 1316-1328. https://doi.org/10.1111/jgh.14664
[20]
Li, M., Oshima, T., Horikawa, T., et al. (2018) Systematic Review with Meta-Analysis: Vonoprazan, a Potent Acid Blocker, Is Superior to Proton-Pump Inhibitors for Eradication of Clarithromycin-Resistant Strains of Helicobacter pylori. Helicobacter, 23, e12495. https://doi.org/10.1111/hel.12495
[21]
Ma, Y., Sun, Q., Wang, S., et al. (2022) Clinical Study of Fumaric Acid Levonor Tablet in the Treatment of Patients with Recurrent Reflux Esophagitis. Chinese Journal of Clinical Pharmacology, 38, 1735-1738. (In Chinese).
[22]
Zheng, Y.H., Zhao, X.Y. and Wei, Z.P. (2022) Observation on the Therapeutic Effect of Fumaric Acid Levonor in the Treatment of Refractory Reflux Esophagitis. Practical Pharmacy and Clinical Remedies, 25, 808-812. (In Chinese).
[23]
Zheng, Y., Wang, W.B. and Shan, C.Y. (2022) Clinical Effect of Fumaric Acid Levonor Tablet Combined with Lansoprazole in the Treatment of Laryngopharyngeal Reflux Disease. Chinese Medical Guide, 19, 103-106. (In Chinese).
[24]
Kahrilas, P.J., Falk, G.W., Johnson, D.A., et al. (2000) Esomeprazole Improves Healing and Symptom Resolution as Compared with Omeprazole in Reflux Oesophagitis Patients: A Randomized Controlled Trial. Alimentary Pharmacology & Therapeutics, 14, 1249-1258. https://doi.org/10.1046/j.1365-2036.2000.00856.x
[25]
Röhss, K., Lind, T. and Wilder-Smith, C.(2004) Esomeprazole 40 Mg Provides More Effective Intragastric Acid Control Than Lansoprazole 30 mg, Omeprazole 20 mg, Pantoprazole 40 mg and Rabeprazole 20 mg in Patients with Gastro-Oesophageal Reflux Symptoms. European Journal of Clinical Pharmacology, 60, 531-539. https://doi.org/10.1007/s00228-004-0804-6
[26]
Matsukawa, J., Hori, Y., Nishida, H., Kajino, M. and Inatomi, N. (2011) A Comparative Study on the Modes of Action of TAK-438, a Novel Potassium-Competitive Acid Blocker, and Lansoprazole in Primary Cultured Rabbit Gastric Glands. Biochemical Pharmacology, 81, 1145-1151. https://doi.org/10.1016/j.bcp.2011.02.009
[27]
Xiao, Y., Zhang, S., Dai, N., et al. (2020) Phase III, Randomised, Double-Blind, Multicentre Study to Evaluate the Efficacy and Safety of Vonoprazan Compared with Lansoprazole in Asian Patients with Erosive Oesophagitis. Gut, 69, 224-230. https://doi.org/10.1136/gutjnl-2019-318365
[28]
Tanabe, T., Hoshino, S., Kawami, N., et al. (2019) Efficacy of Long-Term Maintenance Therapy with 10-mg Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis. Esophagus, 16, 377-381. https://doi.org/10.1007/s10388-019-00676-x
[29]
Jung, D.H., Huh, C.W., Lee, S.K., et al. (2021) A Systematic Review and Meta-analysis of Randomized Control Trials: Combination Treatment with Proton Pump Inhibitor plus Prokinetic for Gastroesophageal Reflux Disease. Journal of Neurogastroenterology and Motility, 27, 165-175. https://doi.org/10.5056/jnm20161
[30]
Lee, J.Y., Kim, S.K., Cho, K.B., et al. (2017) A Double-Blind, Randomized, Multicenter Clinical Trial Investigating the Efficacy and Safety of Esomeprazole Single Therapy Versus Mosapride and Esomeprazole Combined Therapy in Patients with Esophageal Reflux Disease. Journal of Neurogastroenterology and Motility, 23, 218-228. https://doi.org/10.5056/jnm16100
[31]
Lind, T., Rydberg, L., Kylebäck, A., et al. (2000) Esomeprazole Provides Improved Acid Control vs. Omeprazole in Patients with Symptoms of Gastro-Oesophageal Reflux Disease. Alimentary Pharmacology & Therapeutics, 14, 861-867. https://doi.org/10.1046/j.1365-2036.2000.00813.x
[32]
Yu, E.W., Bauer, S.R., Bain, P.A. and Bauer, D.C. (2011) Proton Pump Inhibitors and Risk of Fractures: A Meta-Analysis of 11 International Studies. The American Journal of Medicine, 124, 519-526. https://doi.org/10.1016/j.amjmed.2011.01.007
[33]
Lazarus, B., Chen, Y., Wilson, F.P., et al. (2016) Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Internal Medicine, 176, 238-246. https://doi.org/10.1001/jamainternmed.2015.7193
[34]
Heidelbaugh, J.J., Goldberg, K.L and Inadomi, J.M. (2009) Overutilization of Proton Pump Inhibitors: A Review of Cost-Effectiveness and Risk [Corrected]. American Journal of Gastroenterology, 104, S27-S32.
